

免疫細胞與標靶精準治療在骨髓性腫瘤的新發展

Immunotherapy and targeted therapy for myeloid malignancies

白禮源

中國醫藥大學附設醫院 內科部血液腫瘤科

With the advance of diagnostic tools, pharmacotherapeutics and supportive care, the overall survival of patients with acute myeloid leukemia (AML) has increased. However, despite the progress, the treatment of AML using chemotherapy probably reaches the limit. The research in the molecular characteristic of AML has identified several important pathogenic pathways or molecules which can be exploited using targeted strategies. The methods include small molecules, unconjugated antibodies targeting one or more antigens and antibodies armed with drugs, toxic proteins, or radioisotopes. Several novel agents targeting the key pathways or molecules have been tested in clinical trials of AML, with some with promising results. In CML, the efficacy of targeted therapy with pathogenic bcr-abl inhibitors has been recognized and nowadays is the standard first line therapy.

In last decade, there is a surge in successful immunotherapies for patients with various solid tumors or lymphoid malignancies. For AML, the role of immunotherapy is less defined. In this meeting, we will discuss the evidence, recent progress and future perspectives of targeted therapy and immunotherapy for patients with myeloid malignancies.